Hormone Therapy in Breast and Prostate Cancer (Cancer Drug Discovery and Development)

Northwestern Univ., Chicago, IL. Presents a review of the endocrine treatment of breast and prostate cancer by the originators, a model for making new discoveries in the chemoprevention of cancer, a synthesis of history and clinical practice, and a guide for progress. DNLM: Breast Neoplasms--drug therapy. ASD ZONE......Page 1 CONTENTS......Page 12 1 An Introduction to the Regulation of Sex Steroids for the Treatment of Cancer......Page 18 Part I: Preclinical Antiestrogens......Page 31 2 Antiestrogens and the Cell Cycle......Page 32 3 Drug Resistance to Antiestrogens......Page 61 4 Mechanisms of Liver Carcinogenesis by Antiestrogens......Page 83 5 The Effects of Triphenylethylene Antiestrogens on Parameters of Multistage Hepatocarcinogenesis in the Rat......Page 96 6 Preclinical Studies of Raloxifene and Related Compounds......Page 145 7 Pure Antiestrogens......Page 172 Part II: Antiestrogens: Clinical......Page 193 8 Tamoxifen for the Treatment of Breast Cancer......Page 194 9 Clinical Utility of New Antiestrogens......Page 203 10 Breast Cancer Prevention with Antiestrogens......Page 221 Part III: Inhibition of Estrogen Synthesis......Page 240 11 Aromatase Inhibitors......Page 241 12 Clinical Utility of Aromatase Inhibitors......Page 270 13 LH-RH Agonists for the Treatment of Breast Cancer:......Page 297 Part IV: Androgens and Androgen Withdrawal......Page 313 14 Molecular Action of Androgens......Page 314 15 Steroidal Antiandrogens......Page 328 16 Nonsteroidal Antiandrogens......Page 350 17 LH-RH Agonist Role in Prostate Cancer Management......Page 372 Part V: Perspective on Progress......Page 386 18 Recent Progress in Breast Cancer Research......Page 387 Index......Page 411 Millions of people are now successfully using hormone antagonists for the treatment of endocrine-dependent cancers. In Hormone Therapy in Breast and Prostate Cancer, many of today's leading researchers and clinicians describe the principles underlying these targeted treatments, assess the actions of new and established agents, and illustrate the new applications of hormonal chemoprevention for breast cancer. Topics range from preclinical and clinical antiestrogens to the inhibition of estrogen synthesis and the effects of androgen withdrawal. A wide variety of proven and new agents are discussed-antiestrogens, including aromatase inhibitors (anastrozole, letrozole, and others), SERMs (tamoxifen, raloxifene, and others), and such antiandrogenic strategies as goserelin and bicalutamide. Unique in its synthesis, Hormone Therapy in Breast and Prostate Cancer offers medical and surgical oncologists, urologists, physicians, and clinical pharmacologists a sound basis for understanding targeted treatments of breast and prostate cancers, and provides a well-proven model for developing powerful new cancer therapeutics. In Hormone Therapy in Breast and Prostate Cancer, many of today’s leading researchers and clinicians describe the principles underlying targeted hormonal treatments, assess the actions of new and established agents, and illustrate the new applications of hormonal chemoprevention for breast cancer. Topics range from preclinical and clinical antiestrogens to the inhibition of estrogen synthesis and the effects of androgen withdrawal. A wide variety of proven and new agents are discussed—antiestrogens, including aromatase inhibitors (anastrozole, letrozole, and others), SERMs (tamoxifen, raloxifene, and others), and such antiandrogenic strategies as goserelin and bicalutamide.

researchers And Clinicians Describe The Principles Underlying The Use Of Hormone Antagonists For The Treatment Of Endocrine-dependent Cancers. They Assess The Actions Of New And Established Agents And Illustrate New Applications Of Hormonal Chemoprevention For Breast Cancer. The Contributors, Representing Both Academia And Industry In The Us, Europe, Australia, And Japan, Cover History, Laboratory Discovery, And Clinical Practice. Of Interest To Medical And Surgical Oncologists, Urologists, Cancer Researchers, Physicians, And Pharmacologists. Annotation C. Book News, Inc., Portland, Or (booknews.com)

The reduction of circulating steroid hormones or the blockade of steroid action in cancer tissue are primary goals in the current strategy of breast- and prostate-cancer treatment.